Large study suggests blood plasma can help treat Covid-19, with caveats
Quickly administering convalescent plasma had a marked effect on mortality for patients with severe disease. But the study also lacked a control group.
Quickly administering convalescent plasma had a marked effect on mortality for patients with severe disease. But the study also lacked a control group.
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
The drug industry officially has two new heavyweights. For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold. They join…
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. |…
Newly named partner Anthony Philippakis and managing partner Krishna Yeshwant spoke with BioPharma Dive about biotech’s newfound optimism and their investing “North Star.”
CSL’s cholesterol efflux enhancer failed to prevent repeat cardiac events in a Phase III study that recruited patients who had a recent myocardial infarction, prompting…
Background: The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been…
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data.
This randomized clinical trial compares the effects of evolocumab vs placebo on change in percent atheroma volume among adult patients with angiographic coronary disease despite…
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data.